熱門資訊> 正文
Moderna在埃博拉疫苗第一阶段试验开始后崛起
2026-08-05 01:38
- Moderna (MRNA) said that the first patients have been immunized in a phase 1 Canadian trial examining its mRNA vaccine mRNA-1469 to prevent Bundibugyo ebolavirus (BDBV).
- About 80 healthy adult participants will take part in the study, which is being conducted with the support of the Coalition for Epidemic Preparedness Innovations, which has dedicated up to $50M for preclinical and phase 1 testing.
- If the vaccine is eventually licensed, Moderna will provide a minimum of 500,000 doses for low- and middle-income countries under access pricing.
- This variant of Ebola is the source of an outbreak in the Democratic Republic of the Congo. As of July 30, there have been 3605 confirmed BDBV cases there, which include 1587 deaths, according to the World Health Organization.
More on Moderna
- Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript
- Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now
- Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science
- July healthcare recap: Regeneron, DexCom shine as Moderna, managed-care stocks retreat
- Moderna reiterates up to 10% 2026 revenue growth while lowering cash cost guidance to ~$4B
推薦文章
港股周報 | 黃金股狂飆！靈寶黃金周升24%；段永平「被動減持」泡泡瑪特；藥明康德升近20%創新高
一周財經日曆 | 重磅財報周！騰訊、Lumentum、中芯國際輪番登場！美國7月CPI攜零售數據來襲
8月8日外盤頭條：伊朗內部辯論霍爾木茲協議措辭 非農爆冷削弱加息預期 SpaceX將自建發電廠保障電力供應
Palantir股價將創下自2024年以來最佳單周表現，該股已不再是AI領域的失意者
7月非農就業數據走弱，支持美聯儲維持利率不變，但加息選項並未徹底排除
美股前瞻 | 聚焦20：30！市場靜候7月非農數據；特朗普政府擬加碼佈局關鍵礦產；應用光電計劃大規模擴產，光通信盤前集體飆升
港股異動 | 創新葯概念再度走強，再鼎新葯勁升14%，Q2產品收入環比增長11%；藥明生物升逾5%，百濟神州升逾3%
港股異動 | AI硬件股多數上漲，建滔積層板、勝宏科技漲逾5%，兆易創新漲逾3%；南方兩倍做多海力士跌逾9%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
